Sign in
Taking people in Hong KongNo phase

Comparing two endoscopic treatments to prevent repeat bleeding from varices in liver cancer

Compares ultrasound-guided and standard endoscopic treatment in adults with liver cancer and recent variceal bleeding.

Key facts

Who runs it
Chinese University of Hong Kong
Where
Shatin, Hong KongSee the site
Trial code
Registry title
Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients
Status
Recruiting
People taking part
84 people, planned
Started
22 Nov 2022
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • endoscopic ultrasound-guided therapy
  • conventional endoscopic therapy
Record updated
19 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with liver cancer (hepatocellular carcinoma) who recently bled from swollen veins in the food pipe or stomach, and whose bleeding was stopped by standard endoscopy treatment.

Age
18 years or older
Sex
All sexes can join
Disease stage
Hepatocellular carcinoma with a recent bleed (within 4 weeks) from swollen veins (varices) in the food pipe (esophagus) or stomach. The bleeding was stopped by standard endoscopic treatment.
Earlier treatment
The bleeding must have been controlled by standard endoscopic therapy: band ligation (VBL) for food pipe varices, or glue injection for stomach varices.

Main reasons for not taking part

  • Cannot give written informed consent
  • Cannot have endoscopy because of other illnesses
  • Gastrointestinal bleeding from a source other than varices
  • Blood clotting problem (INR above 1.5) or low platelets (below 50,000) that persist despite blood product transfusion
  • Dying from a terminal illness

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Consecutive HCC patients age 18 or older with recent (within 4 weeks of the episode) EV or GV bleeding successfully controlled by conventional endoscopic therapies (VBL for EV or glue injection for GV)
  • Able to provide written informed consent to participate in the study and comply with the study procedures

Who cannot take part

  • HCC patients with non-variceal source of gastrointestinal bleeding
  • Moribund patients from terminal illness
  • Refractory coagulopathy (INR>1.5) or refractory thrombocytopenia (platelets <50,000) despite blood product transfusion
  • Unable to provide written informed consent
  • Contraindications for endoscopy due to underlying comorbidities

Where in Hong Kong

  • Prince of Wales Hospital, The Chinese University of Hong KongShatin, Hong KongContact: Felix Siz, BSTaking people

About the trial

What the trial wants to find out

Rebleeding rate is high in hepatocellular carcinoma (HCC) patients with variceal bleeding despite conventional endoscopic therapies for esophageal and gastric varices (EV, GV). Secondary prevention of variceal rebleeding was reported to improve outcomes of HCC patients, but the optimal endoscopic approach is not well defined. In this difficult-to-manage population, variceal rebleeding rates remain substantial after conventional endoscopic therapies. n recent studies by others and our group on direct EUS-guided therapy for varices in cirrhotic patients, high technical success (90 - 100%), low post-treatment rebleeding rate (3 - 11%) and low adverse event rate (~3%) have been reported for GV treatment by cyanoacrylate glue injection, coiling or a combination of both, and for cyanoacrylate glue injection or coiling of EV refractory to variceal band ligation (VBL). This study aims to compare rebleeding rates after secondary prevention by EUS-guided therapy or conventional endoscopic therapy in HCC patients with recent variceal bleeding.

The 2 groups in the trial

  • EUS-guided therapy groupExisting treatment, for comparison

    EUS would be performed with a curvilinear echoendoscope based on protocol described in our prior study. Because EUS-guided glue injection can be applied to both EV and GV and is less technically demanding than coiling or the combination approach, it is chosen as the EUS guided intervention in our study. The target EV or GV size will be measured by the caliper function on the EUS machine. After confirmation of blood flow in the target varix by Doppler, EUS-guided glue injection would be performed for EV or GV ≥ 3mm in diameter using a standard 19G needle. Each injection will contain a 1.2ml mixture of 0.5ml glue (Histoacryl, n-butyl-2-cyanoacrylate, B. Braun Surgical, Germany) + 0.7ml lipiodol. Flow obliteration in the treated varix will be confirmed on EUS Doppler. If blood flow is still observed on Doppler after the first injection, additional injection of glue-lipiodol mixture would be repeated (up to 4 doses) until flow obliteration is achieved.

    Treatment: endoscopic ultrasound-guided therapy

  • Conventional endoscopic therapy groupExisting treatment, for comparison

    In patients with prior EV bleeding, EV with high-risk stigmata (regardless of size) or EV of medium or large size detected on study EGD will be treated with VBL using a multi-band ligator fitted on the gastroscope for secondary prevention. In patients with prior GV bleeding, if compressible GV suggestive of incomplete obliteration from prior glue treatment is noted on study EGD, cyanoacrylate glue injection using a 1.2ml mixture of 0.5ml glue (Histoacryl, n-butyl-2-cyanoacrylate, B. Braun Surgical, Germany) + 0.7ml lipiodol will be performed for secondary prevention.

    Treatment: conventional endoscopic therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Secondary Prevention of Variceal Rebleeding by Endoscopic Ultrasound-guided Therapy Versus Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients: a Randomized Controlled Trial
Plain-language title
Comparing two endoscopic treatments to prevent repeat bleeding from varices in liver cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
19 March 2026